This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Currently Amended) Use of silibinin, its salts and/or its pro-drugs with a lipoic acid, its salts and/or its pro-drugs for the production of a medicine for the simultaneous, separate or timed A method for the cytoprotective treatment of chronically obstructive lung, comprising administering to a subject in need thereof an effective dose of

(a) sibilin or a salt thereof

and

(b) α-lipoic acid or a salt thereof,

wherein each of (a) and (b) are administered to said subject by inhalation in a simultaneous, separate, or timed manner diseases.

Claim 2. (Currently Amended) Use The method according to claim 1, characterised in that the dose of the  $\alpha$  lipoic acid, its salts and/or its pro drugs for administration to wherein said subject is a human patient and the dose of said  $\alpha$ -lipoic acid or a salt thereof is between 30 and 1800 mg/d, preferably between 200 and 600 mg/d.

Claim 3. (Currently Amended) Use The method according to Claim 1, characterised in that the dose of silibinin, its salts and/or its pro-drugs for administration to wherein said subject is a human patient and the dose of said sibilin or a salt thereof is between 20 and 1600 mg/d, preferably between 300 and 800 mg/d.

Claim 4. (Cancelled)

Claim 5. (Currently Amended) Use The method according to Claim 1, comprising administering to said subject an additive which is an aqueous solvent, a stabilizer, a suspending agent, a dispersing agent or a wetting agent characterised in that the medicine contains further additives selected from the group of aqueous solvents, stabilisers, suspending, dispersing and wetting agents.

Claim 6. (Currently Amended) Use The method according to Claim 1, characterised in that the medicine wherein each of (a) and (b) is presented in the form of an aerosol, a solution, granules, a powder, an emulsion, a tablet and/or a film tablet.

Claim 7. (Currently Amended) Use The method according to Claim 1, characterised in that silibinin, its salts and/or its pro drugs or a salt thereof and the  $\alpha$ -lipoic acid, its salts and/or its pro drugs are or a salt thereof is presented in a single formulation.

Claim 8. (Currently Amended) Use The method according to Claim 1, characterised in that silibinin, its salts and/or its pro drugs or a salt thereof and the  $\alpha$ -lipoic acid, its salts and/or its pro-drugs or a salt thereof are presented in separate formulations.

## Claim 9. (Cancelled)

Claim 10. (Currently Amended) Use The method according to Claim 1, characterised in that the wherein an effector of glutathione metabolism and the  $\alpha$ -lipoic acid, its salts and/or its prodrugs or a salt thereof are presented in a single formulation.

Claim 11. (Currently Amended) Use The method according to Claim 1, eharacterised in that the wherein an effector of glutathione metabolism and the  $\alpha$ -lipoic acid, its salts and/or its prodrugs or a salt thereof are presented in separate formulations.

Claim 12. (Currently Amended) Use The method according to claim 1 comprising administering to said subject silibilin and  $\alpha$ -lipoic acid. for the simultaneous, separate or timed eytoprotective treatment of chronically obstructive lung diseases comprising administering silibinin, its salts and/or its pro-drugs with  $\alpha$  lipoic acid

Claim 13. (New) The method according to claim 2, wherein the dose of  $\alpha$ -lipoic acid or a salt thereof is between 200 and 600 mg/d.

Claim 14. (New) The method according to claim 3, wherein the dose of sibilin or a salt thereof is between 300 and 800 mg/d.

Serial No.: 10/584,072 -3- PMP-0003

Claim 15. (New) The method according to Claim 1, wherein said subject is a human patient and the dose of said sibilin or a salt thereof is between 20 and 1600 mg/d and the dose of said  $\alpha$ -lipoic acid or a salt thereof is between 30 and 1800 mg/d.

Serial No.: 10/584,072 -4- PMP-0003